This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Dutasteride

Read time: 1 mins
Marketing start date: 23 Dec 2024

Summary of product characteristics


Effective Time

20221105

Version

5

Spl Product Data Elements

Dutasteride Dutasteride DUTASTERIDE DUTASTERIDE BUTYLATED HYDROXYTOLUENE GELATIN GLYCERIN METHYLPARABEN PROPYLPARABEN TITANIUM DIOXIDE ALCOHOL FERROSOFERRIC OXIDE ISOPROPYL ALCOHOL POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ACETATE PHTHALATE PROPYLENE GLYCOL CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES AMMONIA WATER OPAQUE-WHITE Oblong Shaped 641

Application Number

ANDA204373

Brand Name

Dutasteride

Generic Name

Dutasteride

Product Ndc

70771-1347

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1347-3 in bottle of 30 capsules Dutasteride Capsules, 0.5 mg R x only 30 Capsules container label

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.